{"nctId":"NCT01885559","briefTitle":"HALT Progression of Polycystic Kidney Disease Study B","startDateStruct":{"date":"2006-01","type":"ACTUAL"},"conditions":["Kidney, Polycystic"],"count":486,"armGroups":[{"label":"ACE-I + placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Lisinopril","Drug: Placebo"]},{"label":"ACE-I + ARB","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Lisinopril","Drug: Telmisartan"]}],"interventions":[{"name":"Lisinopril","otherNames":["ACE-I","ACE","Ace-Inhibitor"]},{"name":"Telmisartan","otherNames":["ARB"]},{"name":"Placebo","otherNames":["Control"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of ADPKD.\n* Age 15-49 (Study A); Age 18-64 (Study B).\n* GFR \\>60 mL/min/1.73 m2 (Study A); GFR 25-60 mL/min/1.73 m2 (Study B).\n* BP ≥130/80 or receiving treatment for hypertension.\n* Informed Consent.\n\nExclusion Criteria:\n\n* Pregnant/intention to become pregnant in 4-6 yrs.\n* Documented renal vascular disease.\n* Spot urine albumin-to-creatinine ratio of \\>0.5 (Study A) or ≥1.0 (Study B) and/or findings suggestive of kidney disease other than ADPKD.\n* Diabetes requiring insulin or oral hypoglycemic agents / fasting serum glucose of \\>126 mg/dl / random non-fasting glucose of \\>200 mg/dl.\n* Serum potassium \\>5.5 milliequivalent (mEq) /L for participants currently on ACE-I or ARB; \\>5.0 mEq/L for participants not currently on ACE-I or ARB.\n* History of angioneurotic edema or other absolute contraindication for ACE-I or ARB. Intolerable cough associated with ACE-I is defined as a cough developing within six months of initiation of ACE-I in the absence of other causes and resolving upon discontinuation of the ACE-I.\n* Indication (other than hypertension) for β-blocker or calcium channel blocker therapy (e.g. angina, past myocardial infarction, arrhythmia), unless approved by the site principal investigator. (PI may choose to accept an individual who is on only a small dose of one of these agents and would otherwise be eligible.)\n* Systemic illness necessitating nonsteroidal antiinflammatory drugs (NSAIDs), immunosuppressant or immunomodulatory medications.\n* Systemic illness with renal involvement.\n* Hospitalized for acute illness in past 2 months.\n* Life expectancy \\<2 years.\n* History of non-compliance.\n* Unclipped cerebral aneurysm \\>7mm diameter.\n* Creatine supplements within 3 months of screening visit.\n* Congenital absence of a kidney (also total nephrectomy for Study B).\n* Known allergy to sorbitol or sodium polystyrene sulfonate.\n* Exclusions specific to magnetic resonance (MR) imaging (Study A).","healthyVolunteers":false,"sex":"ALL","minimumAge":"15 Years","maximumAge":"64 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With 50% Reduction of Baseline eGFR, End Stage Renal Disease (ESRD, Initiation of Dialysis or Preemptive Transplant), or Death.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"116","spread":null},{"groupId":"OG001","value":"115","spread":null}]}]}]},{"type":"SECONDARY","title":"Albuminuria","description":"Annual percent change in 24 hour urine albumin, centrally processed. Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope of the model). The measure presented is the average annual percent change across the 8 years.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":null},{"groupId":"OG001","value":"7.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Aldosterone","description":"Annual percent change in urinary aldosterone, centrally processed measure. Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope for time from the model). The measure presented is the average annual percent change across the 8 years.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.8","spread":null},{"groupId":"OG001","value":"-10.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Hospitalizations","description":"Hospitalization for any cause","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"173","spread":null},{"groupId":"OG001","value":"136","spread":null}]}]}]},{"type":"SECONDARY","title":"Cardiovascular Hospitalizations","description":"Cause-specific hospitalizations (cardiovascular)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Quality of Life Physical Component Summary","description":"Short Form-36 Quality of Life Physical Component Summary ranges from 0 (worst possible outcome) to 100 (best possible outcome). Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope for time from the model). The measure presented is the average annual change across the 8 years.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.64","spread":null},{"groupId":"OG001","value":"-0.68","spread":null}]}]}]},{"type":"SECONDARY","title":"Quality of Life Mental Component Summary","description":"Short Form-36 Quality of Life Mental Component Summary ranges from 0 (worst possible outcome) to 100 (best possible outcome). Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope for time from the model). The measure presented is the average annual change across the 8 years.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.031","spread":null},{"groupId":"OG001","value":"-0.079","spread":null}]}]}]},{"type":"SECONDARY","title":"Back or Flank Pain","description":"Report of back or flank pain since the last visit (yes or no)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":88,"n":242},"commonTop":["Hyperkalemia","Acute Kidney Injury"]}}}